

Phosphagenics Appoints Three New Non-Executive Directors

3 March 2014, Melbourne: Australian drug delivery technology company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY) has appointed biotech industry veterans Mr Lawrence Gozlan, Mr Nathan Drona and Dr Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis.

Mr Stuart James, Dr Sandra Webb, Mr Don Clarke and Mr Jonathan Addison have retired from the Board. The Company thanks them for their contributions over many years.

Mr Lawrence Gozlan has been a leading fund manager and analyst in the Australian biotech sector over the past decade. He is the Chief Investment Officer and founder of global investment fund Scientia Capital, which specialises in managing investments for domestic and international institutional investors in the life science sector. Prior to this, Mr Gozlan was the biotech analyst for QIC, the largest Australian institutional investor in life sciences at the time.

Mr Gozlan is currently a director of Oncosil Medical Ltd (ASX: OSL) and Prana Biotechnology Ltd (ASX:PBT), one of the best performing biotech companies in the past 12 months. Last year Mr Gozlan was appointed to the board of AusBiotech Ltd, Australia's main life sciences industry body.

Mr Nathan Drona joins the Board following a 15 year career in international investment banking, most recently as Managing Director of Challiss in New York and Sydney. MrDrona has a strong background in corporate finance and has executed over 25 global banking and M&A engagements in biotech, medical devices and healthcare, leading to the award of "Pharmaceutical Buy-Side M&A Advisor of the Year" by Frost & Sullivan in 2005.

Nathan is a non-executive director of Alchemia Limited, which he joined in March 2013. Alchemia is one of Australia's more successful biotech companies with one drug in late stage clinical development and an FDA-approved drug with sales. He has also been a board member of other public and private companies in Australia and North America.

Dr Geert Cauwenbergh is very experienced in the life sciences sector having started his career with Janssen Research Foundation in 1979 in Belgium. He moved to the US in 1994 to take up the role of Vice President of Product Development for J&J. Subsequently he was appointed Global Vice President of R&D for J&J Consumer Companies worldwide.

In 2001 Dr Cauwenbergh left J&J and founded Barrier Therapeutics, a company developing drugs to treat skin diseases. Barrier Therapeutics was acquired by Stiefel Laboratories in 2008. At the time of the acquisition the company's annual revenues had reached approximately US\$45 million.

DrCauwenbergh is currently President and CEO of OTC listed company RXi Pharmaceuticals (OTC:RXII). In this role he has guided RXII through its initial public offering and helped it successfully prepare and submit its first US FDA Investigational New Drug Application.

Mr Harry Rosen, Chief Executive Officer of Phosphagenics, said, "We welcome Lawrence, Geert and Nathan to our Board. They represent the new generation of well-credentialed directors who are committed to strong corporate governance with determination to create shareholder value.

"They join the Board on the cusp of Phosphagenics commercialising our lead product, the oxymorphone pain relief patch. Their commercialisation experience, contacts and advice will be invaluable during this transformational time.

"I take this opportunity to thank all four retiring directors for their many years of dedicated service and invaluable contributions to our Company."

Mr Gozlan said, "Nathan, Geert and I are delighted to join the Company at this time with such a compelling technology targeting large unmet medical needs. The results from the oxymorphone patch trial, announced in October, indicate the Company is well on the way to finalising development and commercialisation of this novel and valuable product. We look forward to continuing to revamp Phosphagenics and help drive commercialisation and also look forward to potential additions to the board and senior executive team in the future."

Enquiries

Harry Rosen
Chief Executive Officer
Phosphagenics Limited
+61 3 9565 1119

David Segal
Investor Relations Manager
Phosphagenics Limited
+61 3 9565 1103

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Phosphagenics

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM[®] – Targeted Penetration Matrix technology. TPM[®] is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead products advancing through clinical trials are an oxymorphone and oxycodone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

Forward-looking Statements

Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

www.phosphagenics.com

www.bioelixia.com